세계의 약물전달장치 시장 : 제품별(분무기, 공기흡입기, 주사기, 주사기, 경피용 패치, 드롭병, 펜형 주사기, 이식형 장치), 치료영역별(당뇨병, 감염, 종양, 호흡기, 심혈관, 자가면역질환) - 예측(-2030년)

Drug Delivery Devices Market by Product (Nebulizer, Inhaler, Syringe, Transdermal Patch, Drop Bottle, Pen Injector, Implantable Device), Therapeutic Area (Diabetes, Infectious, Oncology, Respiratory, Cardiovascular, Autoimmune) - Global Forecast to 2030

US $ 4,175 ￦ 5,876,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회만 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,875 ￦ 8,269,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,875 ￦ 11,084,000

PDF (Global Site License)

PDF 보고서를 동일 기업 및 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 종합적인 1차 및 2차 조사, 시장 시나리오에 대한 심층 분석을 바탕으로 업계의 주요 동인, 제약, 과제와 기회를 제공합니다. 이 시장의 성장은 만성 질환의 유병률 증가, 질병 치료 접근법의 발전, 제약 및 생명공학 부문의 R&D 비용 증가, 첨단 약물 전달 시스템에 대한 수요 증가 등에 의해 주도되고 있습니다. 그러나 제조상의 결함, 새로운 약물 전달 시스템에 대한 인식 및 교육 부족으로 인해 시장 성장이 제한되고 있습니다.

또한, 신흥국 및 약물 전달 시스템의 기술 발전은 시장 성장의 기회를 창출할 것으로 예상됩니다. 그러나 생체 적합성 및 수용성에 대한 우려는 시장 성장에 영향을 미치는 과제 중 하나입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

• 개요
• 성장 촉진요인
• 성장 억제요인
• 기회
• 과제
• 동향
• 규제 시나리오
• 가격 분석
• 밸류체인 분석

제5장 세계의 약물전달 기기 시장 : 제품별

• 개요
• 경비/경폐 약물전달 시스템
  • 네뷸라이저
    • 제트 네뷸라이저
    • 초음파 네뷸라이저
    • 메시 네뷸라이저
  • 공기 흡입기
    • 정량 흡입기
    • 소프트 미스트 흡입기
    • 드라이 파우더 흡입기
  • 스티마
  • 비강 스프레이
• 비경구 약물전달 시스템
  • 시린지
    • 기존 시린지
    • 안전 시린지
    • 프리필드 시린지
  • 펜형 주사기
  • 자동 주사기
  • 무바늘 주사기
  • 웨어러블 주사기/체내 약물전달 시스템
• 국소/경피 약물전달 시스템
  • 경피패 치
  • 웨어러블 패치
• 드롭 보틀 약물전달 시스템
  • 점비약 보틀
  • 점안 보틀
  • 인공와우 드롭 보틀
• 이식형 약물전달 기기
  • 인서트
  • 펌프
  • 약물 용출 스텐트
• 인슐린 펌프
• 자궁내 디바이스
• 주입 펌프

제6장 세계의 약물전달 기기 시장 : 치료 영역별

• 개요
• 당뇨병
• 감염증
• 종양
• 심혈관질환
• 호흡기질환
• 신경질환
• 자가면역질환

제7장 약물전달 기기 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 스위스
  • 벨기에
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 인도네시아
  • 싱가포르
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 아랍에미리트(UAE)
  • 사우디아라비아
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제8장 경쟁 분석

• 개요
• 주요 성장 전략
• 경쟁 벤치마킹
• 경쟁 대시보드
  • 시장 리더
  • 차별화 요인
  • 선행 기업
  • 신규 기업
• 주요 기업별 시장 점유율 분석/시장 순위(2022년)

제9장 기업 개요(기업 개요, 재무 개요, 제품 포트폴리오, 전략 전개 상황)

• Koninklijke Philips N.V.
• OMRON Corporation
• GMP Laboratories of America, Inc.
• Gemini Pharmaceuticals, Inc.
• Resyca GmbH
• Novartis International AG
• Becton, Dickinson and Company
• Lifelong Meditech Private Limited
• Bright Pharma Caps, Inc.
• Gerresheimer AG
• West Pharmaceutical Services, Inc.
• Eclam Medical
• SMC Ltd.
• Owen Mumford Limited
• Haselmeier GmbH
• SHL Medical AG
• Ypsomed Holding AG
• AptarGroup, Inc.
• Kindeva Drug Delivery L.P.
• Nemera Group
• Recipharm AB
• Other Companies

(주 : 주요 5개사의 SWOT 분석을 제공 예정)

제10장 부록

LSH

영문 목차

영문목차

The global drug delivery devices market is projected to reach $24.65 billion by 2030, at a CAGR of 7.6% from 2024 to 2030.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. The growth of this market is driven by the increasing prevalence of chronic diseases, advancements in disease treatment approaches, growing R&D expenditures in the pharmaceutical and biotechnology sectors, and increasing demand for advanced drug delivery systems. However, manufacturing defects and a lack of awareness and education about newer drug delivery systems restrain the market's growth.

Furthermore, emerging economies and technological advancements in drug delivery systems are expected to create market growth opportunities. However, concerns related to biocompatibility and acceptability are some of the challenges impacting the market's growth.

Among the products covered in this report, in 2024, the parenteral drug delivery systems segment is expected to account for the largest share of the market. Parenteral drug delivery systems are an invasive type of route taken to administer drugs directly into the bloodstream without undergoing first-pass metabolism. This segment's significant market share is attributed to its effectiveness in delivering active pharmaceutical substances with low bioavailability and a narrow therapeutic index.

Among the therapeutic areas covered in this report, in 2024, the diabetes segment is expected to account for the largest share of the market. Diabetes is a non-communicable and chronic disease that occurs when the body is not able to produce sufficient insulin or cannot use the produced insulin to regulate the sugar a person consumes. This segment's large market share can be attributed to the rising demand for drug delivery devices such as insulin pumps, insulin pens, wearable glucose monitors, and autoinjectors to regulate and track the insulin levels of diabetic patients.

The key players operating in the global drug delivery devices market are Koninklijke Philips N.V. (Netherlands), OMRON Corporation (Japan), GMP Laboratories of America, Inc. (U.S.), Gemini Pharmaceuticals, Inc. (U.S.), Resyca GmbH (Netherlands), Novartis International AG (Switzerland), Becton, Dickinson, and Company (U.S.), Lifelong Meditech Private Limited (India), Bright Pharma Caps, Inc. (U.S.), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Eclam Medical ACS Ltd. (Israel), SMC Ltd. (U.S.), Owen Mumford Limited (U.K.), Haselmeier GmbH (Germany), SHL Medical AG (Switzerland), Ypsomed Holding AG (Switzerland), AptarGroup, Inc. (U.S.), Kindeva Drug Delivery L.P. (U.S.), Nemera Group (France), and Recipharm AB (Sweden).

Scope of the Report:

Drug Delivery Devices Market-by Product

• Nasal & Pulmonary Drug Delivery Systems
  • Nebulizers
• Jet Nebulizers
• Ultrasonic Nebulizers
• Mesh Nebulizers
  • Empty Inhalers
• Metered-Dose Inhalers
• Soft Mist Inhalers
• Dry Powder Inhalers
  • Steamers
  • Nasal Sprays
• Parenteral Drug Delivery Systems
  • Syringes
• Conventional Syringes
• Safety Syringes
• Prefilled Syringes
  • Pen Injectors
  • Autoinjectors
  • Needle Free Injectors
  • Wearable Injectors/On-Body Drug Delivery System
• Topical & Transdermal Drug Delivery System
  • Transdermal Patches
  • Wearable Patches
• Drop Bottle Drug Delivery Systems
  • Nasal Drop Bottles
  • Ocular Drop Bottles
  • Cochlear Drop Bottles
• Implantable Drug Delivery Devices
  • Inserts
  • Pumps
  • Drug-eluting Stents
• Insulin Pumps
• Intrauterine Devices
• Infusion Pumps

Drug Delivery Devices Market-by Therapeutic Area

• Diabetes
• Infectious Diseases
• Oncology
• Cardiovascular Diseases
• Respiratory Diseases
• Neurological Disorders
• Autoimmune Diseases

Drug Delivery Devices Market-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Switzerland
  • Belgium
  • Rest of Europe (RoE)
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Singapore
  • Rest of APAC (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa (RoMEA)

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Increasing Prevalence of Chronic Diseases
  • 4.2.2. Advancements in the Disease Treatment Approaches
  • 4.2.3. Growing R&D Expenditure in Pharmaceutical and Biotechnology Industries
  • 4.2.4. Increasing Demand for Advanced Drug Delivery Systems
• 4.3. Restraints
  • 4.3.1. Manufacturing Defects
  • 4.3.2. Lack of Awareness and Education About Newer Drug Delivery Systems
• 4.4. Opportunities
  • 4.4.1. Emerging Economies
  • 4.4.2. Technological Advancements in Drug Delivery Systems
• 4.5. Challenges
  • 4.5.1. Biocompatibility And Acceptability
• 4.6. Trends
  • 4.6.1. Use of Artificial Intelligence (AI) in Drug Delivery Systems
  • 4.6.2. Evolution in the Connected Drug Delivery Devices
• 4.7. Regulatory Scenario
• 4.8. Pricing Analysis
• 4.9. Value Chain Analysis

5. Global Drug Delivery Devices Market-by Product

• 5.1. Overview
• 5.2. Nasal & Pulmonary Drug Delivery Systems
  • 5.2.1. Nebulizers
    • 5.2.1.1. Jet Nebulizers
    • 5.2.1.2. Ultrasonic Nebulizers
    • 5.2.1.3. Mesh Nebulizers
  • 5.2.2. Empty Inhalers
    • 5.2.2.1. Metered-Dose Inhalers
    • 5.2.2.2. Soft Mist Inhalers
    • 5.2.2.3. Dry Powder Inhalers
  • 5.2.3. Steamers
  • 5.2.4. Nasal Sprays
• 5.3. Parenteral Drug Delivery Systems
  • 5.3.1. Syringes
    • 5.3.1.1. Conventional Syringes
    • 5.3.1.2. Safety Syringes
    • 5.3.1.3. Prefilled Syringes
  • 5.3.2. Pen Injectors
  • 5.3.3. Autoinjectors
  • 5.3.4. Needle-free Injectors
  • 5.3.5. Wearable Injectors/ On-Body Drug Delivery System
• 5.4. Topical & Transdermal Drug Delivery Systems
  • 5.4.1. Transdermal Patches
  • 5.4.2. Wearable Patches
• 5.5. Drop Bottle Drug Delivery Systems
  • 5.5.1. Nasal Drop Bottles
  • 5.5.2. Ocular Drop Bottles
  • 5.5.3. Cochlear Drop Bottles
• 5.6. Implantable Drug Delivery Devices
  • 5.6.1. Inserts
  • 5.6.2. Pumps
  • 5.6.3. Drug Eluting Stents
• 5.7. Insulin Pumps
• 5.8. Intrauterine Devices
• 5.9. Infusion Pumps

6. Global Drug Delivery Devices Market-by Therapeutic Area

• 6.1. Overview
• 6.2. Diabetes
• 6.3. Infectious Diseases
• 6.4. Oncology
• 6.5. Cardiovascular Diseases
• 6.6. Respiratory Diseases
• 6.7. Neurological Disorders
• 6.8. Autoimmune Diseases

7. Drug Delivery Devices Market-by Geography

• 7.1. Overview
• 7.2. North America
  • 7.2.1. U.S.
  • 7.2.2. Canada
• 7.3. Europe
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Switzerland
  • 7.3.7. Belgium
  • 7.3.8. Rest of Europe
• 7.4. Asia-Pacific
  • 7.4.1. Japan
  • 7.4.2. China
  • 7.4.3. India
  • 7.4.4. Australia
  • 7.4.5. South Korea
  • 7.4.6. Indonesia
  • 7.4.7. Singapore
  • 7.4.8. Rest of Asia Pacific
• 7.5. Latin America
  • 7.5.1. Brazil
  • 7.5.2. Mexico
  • 7.5.3. Rest of Latin America
• 7.6. Middle East & Africa
  • 7.6.1. U.A.E.
  • 7.6.2. Saudi Arabia
  • 7.6.3. South Africa
  • 7.6.4. Rest of Middle East & Africa

8. Competition Analysis

• 8.1. Overview
• 8.2. Key Growth Strategies
• 8.3. Competitive Benchmarking
• 8.4. Competitive Dashboard
  • 8.4.1. Market Leaders
  • 8.4.2. Market Differentiators
  • 8.4.3. Vanguards
  • 8.4.4. Emerging Companies
• 8.5. Market Share Analysis/ Market Ranking, By Key Players (2022)

9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

• 9.1. Koninklijke Philips N.V.
• 9.2. OMRON Corporation
• 9.3. GMP Laboratories of America, Inc.
• 9.4. Gemini Pharmaceuticals, Inc.
• 9.5. Resyca GmbH
• 9.6. Novartis International AG
• 9.7. Becton, Dickinson and Company
• 9.8. Lifelong Meditech Private Limited
• 9.9. Bright Pharma Caps, Inc.
• 9.10. Gerresheimer AG
• 9.11. West Pharmaceutical Services, Inc.
• 9.12. Eclam Medical
• 9.13. SMC Ltd.
• 9.14. Owen Mumford Limited
• 9.15. Haselmeier GmbH
• 9.16. SHL Medical AG
• 9.17. Ypsomed Holding AG
• 9.18. AptarGroup, Inc.
• 9.19. Kindeva Drug Delivery L.P.
• 9.20. Nemera Group
• 9.21. Recipharm AB
• 9.22. Other Companies

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

10. Appendix

• 10.1. Available Customization
• 10.2. Related Reports

관련자료